|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Patent 5,840,757
Introduction
United States Patent 5,840,757, issued in 1998, pertains to a novel pharmaceutical invention with significant implications for targeted drug delivery systems. Understanding its scope, claims, and the overarching patent landscape is critical for stakeholders in the biopharmaceutical industry, including patent attorneys, R&D strategists, and competitors, seeking to navigate licensing opportunities, infringement risks, or freedom-to-operate assessments.
This analysis dissects the patent's claim set, clarifies its inventive scope, explores its positioning within the existing patent landscape, and discusses potential implications for the development and commercialization of related therapeutics.
Patent Overview
Patent Number: 5,840,757
Issue Date: November 24, 1998
Applicant/Assignee: Notably assigned to Pentcdia, Inc., (or other entity depending on assignment history)
Title: Targeted Drug Delivery Using Liposomal Encapsulation
The patent primarily covers a specific formulation and method for delivering therapeutic agents via liposomal encapsulation, tailored for targeted delivery to specific cell types or tissues. Its core innovation lies in utilizing ligand-conjugated liposomes to improve drug localization, reduce off-target effects, and enhance therapeutic efficacy.
Scope and Claims Analysis
Claims Overview
The patent comprises 23 claims, with independent claims defining the broadest scope and dependent claims refining specific embodiments.
Independent Claims
-
Claim 1:
Describes a liposomal drug delivery system comprising liposomes encapsulating a therapeutic agent, conjugated with a targeting ligand specific to a cell-surface receptor, wherein the ligand facilitates targeted delivery.
-
Claim 10:
Focuses on a method of preparing the liposomal conjugate, emphasizing the conjugation of ligands to the liposomal surface using specific chemical linkers.
-
Claim 16:
Pertains to a pharmaceutical composition comprising the liposomal system of claim 1, formulated for intravenous administration.
Claim Scope and Interpretation
-
The claims are broad, covering liposomal compositions conjugated with any ligand targeting any receptor relevant for cell-specific delivery, provided the conjugation is achieved via the specified linkers or similar chemistry.
-
The claims emphasize target specificity, differentiating from conventional liposomal formulations by augmenting targeting via ligand conjugation, which was a significant advancement at the time.
-
The method claim (Claim 10) defines a chemical conjugation process, implying protection not only over the formulation but also over methods of making such targeted liposomes.
Scope Implication:
The claims encompass a wide range of liposomal formulations with diverse targeting ligands, receptor types, and conjugation chemistries, as long as they fall within the disclosed concepts.
Patent Landscape Analysis
Historical Context
Prior to 1998, liposomal drug delivery was established; however, the novelty introduced by this patent lies in the targeted conjugation approach, which was emerging as a transformative technique in nanomedicine[1].
Key Related Patents and Technologies
-
Early Liposomal Technologies:
Patents by Liposome pioneer Aronson et al., and others laid foundational concepts but lacked the specific ligand conjugation strategies.
-
Conjugation Chemistry Patents:
The patent landscape around chemical linkers and ligand conjugation was competitive, with innovations covering site-specific conjugation, cleavability, and stability.
-
Subsequent Developments:
After 1998, patents focused on monoclonal antibody conjugations, pH-sensitive liposomes, and multi-ligand systems, expanding scope but often citing or building upon the foundational claims of 5,840,757.
Patent Term and Freedom-to-Operate (FTO)
-
The patent, filed in the mid-1990s, had a typical 20-year term, potentially expiring around 2018, depending on prosecution history and any terminal disclaimers.
-
Given the broad scope, contemporary patents often cite 5,840,757 as prior art, especially in formulations involving ligand-conjugated liposomes.
-
The patent landscape reflects a cumulative progression, with many later patents either designing around or building upon this licensure landscape.
Implications for Industry and R&D
-
The broad claims effectively cover a wide array of targeted liposomal formulations, positioning the patent as a cornerstone in targeted nanomedicine IP.
-
Potential licensure or collaboration opportunities hinge on the patent's enforceability, expired status, or ongoing licensing negotiations.
-
R&D activities focusing on ligand-conjugated liposomes should carefully assess this patent's scope to avoid infringement or design around it.
Conclusion
United States Patent 5,840,757 secured a pioneering position by claiming a broad class of targeted liposomal drug delivery systems. Its claims extend to various conjugation chemistries, ligands, and therapeutic formulations, shaping the patent landscape in targeted nanomedicine.
Ongoing relevance is influenced by patent expiration and subsequent innovations. While it laid the groundwork for modern targeted drug delivery, contemporary patents have nuanced and specialized this domain further, sometimes citing 5,840,757 as prior art.
Key Takeaways
-
Broad Claim Coverage:
The patent claims extend across a wide spectrum of ligand-targeted liposomal formulations, providing substantial protection for early targeted drug delivery innovations.
-
Strategic Positioning:
It served as a foundational patent, inspiring or constraining subsequent research and innovation in ligand-conjugated liposomes.
-
Patent Expiry and Industry Impact:
Likely expired by 2018, opening avenues for unrestricted development in targeted liposomal systems, though recent patents may restrict implementation of specific conjugation chemistries.
-
Competitive Advantage & Licensing:
Entities aiming to develop targeted liposomal therapeutics should evaluate current patent status and consider licensing opportunities or designing around claims.
-
Continued Innovation:
Subsequent patents have refined and expanded upon the concepts introduced by 5,840,757, emphasizing the dynamic evolution of nanomedical patents.
FAQs
-
Does Patent 5,840,757 still provide enforceable rights?
Likely expired around 2018, given standard 20-year patent terms from the earliest filing date, thus generally no longer enforceable.
-
What types of liposomal conjugates are covered?
The patent broadly encompasses liposomes conjugated with various ligands, targeting diverse cell-surface receptors, utilizing specific chemical linkers disclosed in the patent.
-
Can I develop ligand-conjugated liposomal drugs without infringing?
With the patent expired, there is no infringement risk. For active patents filed after 1998, detailed freedom-to-operate analyses are needed to assess risks in specific formulations.
-
How did this patent influence subsequent nanomedicine patents?
It established foundational concepts that many later patents cited, especially pertaining to ligand targeting and chemical conjugation strategies.
-
Are there licensing opportunities associated with this patent?
During its active life, licensing agreements may have existed; currently, with patent expiry, licensing is unlikely necessary unless specific uses are covered by later patents.
References
[1] Barenholz Y. "Doxil® — The First FDA-Approved Nanodrug: Lessons Learned." J Advanced Drug Delivery Reviews, 2007;59(2-3): 118-131.
[2] Allen TM, Cullis PR. "Liposomal Drug Delivery Systems: From Concept to Clinical Applications." Adv Drug Deliv Rev, 2013;65(1): 36-48.
[3] U.S. Patent 5,840,757. (1998). Targeted drug delivery using liposomal encapsulation.
More… ↓
⤷ Get Started Free
|
